HIV/SIV Replication In Vivo

HIV/SIV 体内复制

• 批准号: 9161746
• 负责人: Richard A Koup
• 金额: $ 127.39万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9161746
• 关键词: Anti-Retroviral Agents; CD4 Positive T Lymphocytes; HIV; Immune response; Individual; Patients; SIV; T-Lymphocyte; Vaccines; Virus; base; in vivo

HIV is known to replicate primarily in activated CD4+ T cells. In addition, HIV can remain silent in unactivated T cells - what is referred to as the latent reservoir. Because current anti-retroviral agents only target actively replicating virus, the existance of a latent reservoir is the primary reason why current strategies do not eliminate HIV from people. This study seeks to define the subsets of CD4+ T cells in patients that contain HIV - in both active and latent forms - as a basis to develop strategies to eliminate HIV from the body.

已知HIV主要在活化的CD 4 + T细胞中复制。此外，艾滋病毒可以在未激活的T细胞中保持沉默-这被称为潜在的水库。 由于目前的抗逆转录病毒药物只针对活跃复制的病毒，潜伏储存库的存在是目前的策略不能从人群中消除艾滋病毒的主要原因。 这项研究旨在确定含有HIV的患者的CD 4 + T细胞亚群-以活性和潜伏形式-作为制定从体内消除HIV的策略的基础。